

NOVO NORDISK A S
Form 6-K
August 09, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

May 9, 2018

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Trading in Novo Nordisk shares by board members, executives and associated persons on 8 August 2018

Bagsværd, Denmark, 9 August 2018 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated

a) Name of the Board member/
Executive/Associated Person Jesper Brandgaard

2 Reason for the notification

a) Position/status EVP, Biopharm and Legal Affairs
b) Initial notification/Amendment Initial notification

3 Details of the issuer

a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342

4 Details of the transaction(s)

a) Description of the financial instrument, Shares
type of instrument,

Edgar Filing: NOVO NORDISK A S - Form 6-K

Identification code

Novo Nordisk B DK0060534915

b) Nature of the transaction

Sale of shares

c) Price(s) and volume(s)

Price(s)

Volume(s)

DKK 305.7083 12,500 shares

- d) Aggregated information
- Aggregated volume 12,500 shares
 - Price 305.7083
- e) Date of the transaction 8 August 2018
- f) Place of the transaction Nasdaq
Copenhagen

Definitions and background information:

Publication

Publication shall take place no later than three working days after the trading by board members, executives or their associated persons. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 20,000 EUR.

Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other relatives defined as brothers, sisters, parents, grandparents, children, grandchildren, cousins etc. who have shared the same household with a board member or executive for a period of at least one year on the date of the given transaction and 4) any legal persons, trust, or partnership, the managerial responsibilities of which are discharged by a board member/executive or by a person

referred to in items 1)-3) above, or which is directly or indirectly controlled by such a person, or which is set up for the benefit of such a person, or the economic interests of which are substantially equivalent to those of such a person.

What is trading/transaction?

Trading is any kind of transaction, including shares and share related securities purchased or otherwise acquired, sold or otherwise disposed, gifts, mortgages, heritage and grants, allotments and exercise of options.

What is financial instrument and ID code?

Financial instrument includes shares listed on the Nasdaq Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US- based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.

What is date and place of transaction?

Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, i.e. Nasdaq Copenhagen or New York Stock Exchange.

What is the volume and price of transaction and aggregated information?

The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. In case of a single transaction the price is the price of that single transaction. In case of multiple transactions, when the transactions relates to the same financial instrument, are of the same nature, are executed on the same day and are executed on the same place, the volume must be aggregated. The price of the aggregated transactions is the weighted average price.

The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:

Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

Investors:

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Christina Kjær +45 3079 3009 cnje@novonordisk.com

Novo Nordisk A/S Novo Allé
Investor Relations 2880 Bagsværd
Denmark
Telephone: +45 4444 8888
Internet: www.novonordisk.com
CVR no: 24 25 67 90

Company announcement No 61 / 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: August 9, 2018

Lars Fruergaard Jørgensen

Chief Executive Officer

n 0in;width:12.0%;">

Diversified (39.1%)

Berkshire Hathaway, Inc., Class A*

80,454,001

9,200

Berkshire Hathaway, Inc., Class B*

35,898,400

116,352,401

Diversified Financial Services (1.6%)

106,328

Legg Mason, Inc.

4,734,786

Financial Services (0.8%)

125,000

Citigroup, Inc.

2,373,750

Healthcare Products & Services (1.2%)

52,000

Johnson & Johnson

3,662,360

Insurance (2.0%)

131,000

American International Group, Inc.

2,815,190

120,000

First American Corp.

3,032,400

5,847,590

Manufacturing (3.7%)

150,500

Eaton Corp.

11,013,590

Pharmaceuticals (0.6%)

100,000

Pfizer, Inc.

1,911,000

Real Estate Investment Trust (REIT) (0.5%)

75,000

Redwood Trust, Inc.

1,406,250

Registered Investment Company (RIC) (2.5%)

549,200

Flaherty & Crumrine/Claymore Preferred Securities Income Fund, Inc.

7,370,264

Retail (24.3%)

72,500

The Home Depot, Inc.

1,966,200

177,000

Walgreen Co.

6,448,110

| | |
|--|------------|
| | 370,000 |
| Wal-Mart Stores, Inc. | |
| | 21,855,900 |
| | 1,180,000 |
| Yum! Brands, Inc. | |
| | 42,102,400 |
| | 72,372,610 |
| <i>Savings & Loan Companies (0.4%)</i> | |
| | 317,549 |
| Washington Mutual, Inc. | |
| | 1,286,073 |

Transport - Trucking (2.6%)

| | |
|------------------------------------|-----------|
| | 60,000 |
| Burlington Northern Santa Fe Corp. | |
| | 6,444,000 |
| | 63,100 |
| YRC Worldwide, Inc.* | |
| | 1,142,110 |
| | 7,586,110 |

TOTAL DOMESTIC COMMON STOCKS

(Cost \$160,392,898)

250,414,894

Edgar Filing: NOVO NORDISK A S - Form 6-K

| | | | |
|---|---|--|-----------------------|
| FOREIGN COMMON STOCKS (8.8%) | | | |
| Canada (0.4%) | | | |
| 123,000 | Canfor Pulp Income Fund | | 1,144,509 |
| Hong Kong (3.8%) | | | |
| 515,000 | Cheung Kong Holdings, Ltd. | | 7,403,711 |
| 500,000 | Henderson Investment Ltd., REIT | | 33,314 |
| 104,500 | Henderson Land Development Co., Ltd. | | 636,003 |
| 6,156,000 | Midland Holdings, Ltd. | | 3,155,062 |
| | | | 11,228,090 |
| Japan (0.1%) | | | |
| 340 | New City Residence Investment Corp., REIT | | 492,074 |
| Netherlands (1.5%) | | | |
| 95,117 | Heineken NV | | 4,470,906 |
| New Zealand (1.1%) | | | |
| 4,150,136 | Kiwi Income Property Trust, REIT | | 3,224,434 |
| Turkey (0.0%)(1) | | | |
| 57,183 | Dogus Ge Gayrimenkul Yatirim Ortakligi A.S., REIT* | | 37,652 |
| United Kingdom (1.9%) | | | |
| 75,000 | Diageo PLC, Sponsored ADR | | 5,580,000 |
| TOTAL FOREIGN COMMON STOCKS | | | |
| (Cost \$23,067,017) | | | 26,177,665 |
| AUCTION MARKET PREFERRED SECURITIES (4.1%) | | | |
| 120 | Cohen & Steers Quality Income & Realty Fund, Series M7 | | 3,000,000 |
| 200 | Cohen & Steers REIT & Utility Income Fund, Inc., Series T7 | | 5,000,000 |
| 120 | Duff & Phelps Utility & Corporate Fund | | 3,000,000 |
| 50 | Neuberger Berman Real Estate Securities Income Fund, Series B | | 1,250,000 |
| | | | 12,250,000 |
| TOTAL AUCTION MARKET PREFERRED SECURITIES | | | |
| (Cost \$12,250,130) | | | 12,250,000 |
| TOTAL LONG TERM INVESTMENTS | | | |
| (Cost \$195,710,045) | | | 288,842,559 |
| Par Value | Description | | Value (Note 1) |
| SHORT TERM INVESTMENTS (3.0%) | | | |
| FOREIGN GOVERNMENT BONDS (2.6%) | | | |
| New Zealand (0.8%) | | | |
| 3,550,000 | New Zealand Treasury Bill, 7.120% due 10/15/2008 NZD | | 2,463,837 |
| United Kingdom (1.8%) | | | |
| 2,900,000 | United Kingdom Treasury Bill, 5.050% due 12/1/2008 GBP | | 5,219,209 |
| TOTAL FOREIGN GOVERNMENT BONDS | | | |
| (Cost \$8,267,723) | | | 7,683,046 |
| MONEY MARKET FUNDS (0.4%) | | | |
| 1,123,746 | Dreyfus Treasury, 7 day yield 1.716% | | 1,123,746 |

Edgar Filing: NOVO NORDISK A S - Form 6-K

| | |
|--|-----------|
| TOTAL MONEY MARKET FUNDS (Cost \$1,123,746) | 1,123,746 |
| TOTAL SHORT TERM INVESTMENTS (Cost \$9,391,469) | 8,806,792 |

Edgar Filing: NOVO NORDISK A S - Form 6-K

| | |
|---|----------------|
| TOTAL INVESTMENTS (100.1%) (Cost \$205,101,514) | 297,649,351 |
| TOTAL LIABILITIES LESS OTHER ASSETS (-0.1%) | (307,397) |
| TOTAL NET ASSETS AVAILABLE TO COMMON STOCK AND PREFERRED STOCK (100.0%) | 297,341,954 |
| AUCTION MARKET PREFERRED STOCK (AMPs) REDEMPTION VALUE | (77,500,000) |
| TOTAL NET ASSETS AVAILABLE TO COMMON STOCK | \$ 219,841,954 |

* Non-income producing security.

(1) Less than 0.05% of Total Net Assets.

Common Abbreviations:

ADR - American Depositary Receipt

A.S. - Anonim Sirketi (Turkish: Joint Stock Company)

GBP - British Pound

LP - Limited Partnership

Ltd. - Limited

NV - Naamloze Vennootchap is the Dutch term for a public limited liability corporation

NZD - New Zealand Dollar

PLC - Public Limited Company

See accompanying Notes to Quarterly Portfolio of Investments.

Boulder Total Return Fund, Inc.

August 31, 2008 (Unaudited)

Note 1. Valuation and Investment Practices

Portfolio Valuation: The net asset value of the Fund's Common Stock is determined by the Fund's administrator no less frequently than on the last business day of each week and month. It is determined by dividing the value of the Fund's net assets attributable to common shares by the number of shares of Common Stock outstanding. The value of the Fund's net assets attributable to Common Stock is deemed to equal the value of the Fund's total assets less (i) the Fund's liabilities and (ii) the aggregate liquidation value of the outstanding Taxable Auction Market Preferred Stock. Securities listed on a national securities exchange are valued on the basis of the last sale on such exchange or the NASDAQ Official Close Price on the day of valuation. In the absence of sales of listed securities and with respect to securities for which the most recent sale prices are not deemed to represent fair market value, and unlisted securities (other than money market instruments), securities are valued at the mean between the closing bid and asked prices, or based on a matrix system which utilizes information (such as credit ratings, yields and maturities) from independent sources. Investments for which market quotations are not readily available or do not otherwise accurately reflect the fair value of the investment are valued at fair value as determined in good faith by or under the direction of the Board of Directors of the Fund, including reference to valuations of other securities which are considered comparable in quality, maturity and type. Investments in money market instruments, which mature in 60 days or less at the time of purchase, are valued at amortized cost.

The Fund adopted Financial Accounting Standards Board Statement of Financial Accounting Standards No. 157, Fair Value Measurements (FAS 157), effective December 1, 2007. In accordance with FAS 157, fair value is defined as the price that the Fund would receive upon selling an investment in a timely transaction to an independent buyer in the principal or most advantageous market of the investment. FAS 157 established a three-tier hierarchy to maximize the use of observable market data and minimize the use of unobservable inputs and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, for example, the risk inherent in a particular valuation technique used to measure fair value including such a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The three-tier hierarchy of inputs is summarized in the three broad Levels listed below.

- Level 1 quoted prices in active markets for identical investments
- Level 2 other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)

Edgar Filing: NOVO NORDISK A S - Form 6-K

- Level 3 significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

The valuation techniques used by the Fund to measure fair value during the nine months ended August 31, 2008 maximized the use of observable inputs and minimized the use of unobservable inputs. The Fund utilized the following fair value techniques: multi-dimensional relational pricing model, option adjusted spread pricing and estimated the price that would have prevailed in a liquid market for an international equity given information available at the time of evaluation.

Edgar Filing: NOVO NORDISK A S - Form 6-K

The following is a summary of the inputs used as of August 31, 2008 in valuing the Fund's investments carried at value:

| Valuation Inputs | Investments in Securities |
|---|----------------------------------|
| Level 1 Quoted Prices | \$ 277,716,305 |
| Level 2 Other Significant Observable Inputs | 19,933,046 |
| Level 3 Significant Unobservable Inputs | |
| Total | \$ 297,649,351 |

* Other financial instruments include futures, forwards and swap contracts.

Securities Transactions and Investment Income: Securities transactions are recorded as of the trade date. Realized gains and losses from securities sold are recorded on the identified cost basis. Dividend income is recorded on ex-dividend dates. Interest income is recorded using the interest method.

The actual amounts of dividend income and return of capital received from investments in real estate investment trusts (REITS) and registered investment companies (RICS) at calendar year-end are determined after the end of the fiscal year. The Fund therefore estimates these amounts for accounting purposes until the actual characterization of REIT and RIC distributions is known. Distributions received in excess of the estimate are recorded as a reduction of the cost of investments.

Foreign Currency Translation: The books and records of the Fund are maintained in US dollars. Foreign currencies, investments and other assets and liabilities denominated in foreign currencies are translated in US dollars at the exchange rate prevailing at the end of the period, and purchases and sales of investment securities, income and expenses transacted in foreign currencies are translated at the exchange rate on the dates of such transactions.

Foreign currency gains and losses result from fluctuations in exchange rates between trade date and settlement date on securities transactions, foreign currency transactions and the difference between amounts of interest and dividends recorded on the books of the Fund and the amounts actually received. The portion of foreign currency gains and losses related to fluctuation in exchange rates between the initial purchase trade date and the subsequent sale trade date is included in gains and losses on investment securities sold.

Repurchase Agreements: The Fund may engage in repurchase agreement transactions. The Fund's Management reviews and approves periodically the eligibility of the banks and dealers with which the Fund enters into repurchase agreement transactions. The value of the collateral underlying such transactions is at least equal at all times to the total amount of the repurchase obligations, including interest. The Fund maintains possession of the collateral and, in the event of counterparty default, the Fund has the right to use the collateral to offset losses incurred. There is the possibility of loss to the Fund in the event the Fund is delayed or prevented from exercising its rights to dispose of the collateral securities.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Lending of Portfolio Securities: The Fund used State Street Bank and Trust Company (State Street) as its lending agent during the period to loan securities to qualified brokers and dealers in exchange for negotiated lenders' fees. The Fund received cash collateral, which was invested by the lending agent in short-term money market instruments, in an amount at least equal to the current market value of the loaned securities. The cash collateral was invested in the State Street Navigator Securities Lending Prime Portfolio. To the extent that advisory or other fees paid by State Street Navigator Securities Lending Portfolio were for the same or similar services as fees paid by the Fund, there was a layering of fees, which may have increased expenses and decreased returns. Information regarding the value of the securities loaned and the value of the collateral at period end is included at the end of the Fund's Statement of Assets and Liabilities and Portfolio of Investments in the semi-annual reports to stockholders. Although risk is mitigated by the collateral, the Fund could have experienced a delay in recovering its securities and a possible loss of income or value if the borrower failed to return the securities when due.

As of August 31, 2008, the Fund was not participating in a securities lending program.

Note 2. Unrealized Appreciation/ (Depreciation)

At August 31, 2008, based on cost of \$205,101,514 for federal income tax purposes, aggregate gross unrealized appreciation for all securities in which there is an excess value of over tax cost was \$112,708,334 and aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value was \$20,160,497.

Item 2 - Controls and Procedures.

(a) The Registrant's Principal Executive Officer and Principal Financial Officer concluded that the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (17 CFR 270.300-3(c))) were effective as of a date within 90 days of the filing date of this report (the "Evaluation Date"), based on their evaluation of the effectiveness of the Registrant's disclosure controls and procedures as of the Evaluation Date.

(b) There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940 (17 CFR 270.30a-3(d))) that occurred during the Registrant's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting.

Item 3 Exhibits.

(a) Certification of Principal Executive Officer and Principal Financial Officer of the Registrant as required by Rule 30a-2(a) under the Investment Company Act of 1940 (17 CFR 270.30a-2(a)) is attached hereto as Exhibit 99CERT.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant Boulder Total Return Fund, Inc.

By: /s/ Stephen C. Miller
Stephen C. Miller, President
(Principal Executive Officer)

Date: October 28, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Stephen C. Miller
Stephen C. Miller, President
(Principal Executive Officer)

Date: October 28, 2008

By: /s/ Carl D. Johns
Carl D. Johns, Vice President and Treasurer
(Principal Financial Officer)

Date: October 28, 2008
